Kalaris Therapeutics, Inc. (KLRS) stock
KLRSNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
$1.43−0.03 (-2.05%)
Close on Nov 17, 2026Market cap $34.04MP/E –Yield –
Kalaris Therapeutics total assets
Total assets on the balance sheet at the end of each period.
Kalaris Therapeutics's total assets was $99.54M at Jun 30, 2026. For fiscal 2025 it was $121.74M, up 1875.6% from the year before. The highest annual figure on record is $370.82M in fiscal 2020.
Annual total assets
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $121.74M | +1875.6% |
| FY2024 | Dec 31, 2024 | $6.16M | -96.8% |
| FY2023 | Dec 31, 2023 | $190.80M | -31.1% |
| FY2022 | Dec 31, 2022 | $277.08M | -3.3% |
| FY2021 | Dec 31, 2021 | $286.59M | -22.7% |
| FY2020 | Dec 31, 2020 | $370.82M | +166.0% |
| FY2019 | Dec 31, 2019 | $139.42M | – |
Quarterly total assets
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | $99.54M | +7.2% |
| Q1 FY2026 | Mar 31, 2026 | $109.81M | +6.5% |
| Q4 FY2025 | Dec 31, 2025 | $121.74M | +1875.6% |
| Q3 FY2025 | Sep 30, 2025 | $81.18M | -33.8% |
| Q2 FY2025 | Jun 30, 2025 | $92.84M | -29.1% |
| Q1 FY2025 | Mar 31, 2025 | $103.09M | -28.5% |
| Q4 FY2024 | Dec 31, 2024 | $6.16M | -96.8% |
| Q3 FY2024 | Sep 30, 2024 | $122.53M | -50.7% |
| Q2 FY2024 | Jun 30, 2024 | $130.99M | -53.7% |
| Q1 FY2024 | Mar 31, 2024 | $144.14M | -40.9% |
| Q4 FY2023 | Dec 31, 2023 | $190.80M | -31.1% |
| Q3 FY2023 | Sep 30, 2023 | $248.31M | -15.5% |
| Q2 FY2023 | Jun 30, 2023 | $282.69M | +41.3% |
| Q1 FY2023 | Mar 31, 2023 | $244.04M | +5.6% |
| Q4 FY2022 | Dec 31, 2022 | $277.08M | -3.3% |
| Q3 FY2022 | Sep 30, 2022 | $293.70M | -7.2% |
| Q2 FY2022 | Jun 30, 2022 | $200.00M | -38.9% |
| Q1 FY2022 | Mar 31, 2022 | $231.09M | -34.2% |
| Q4 FY2021 | Dec 31, 2021 | $286.59M | -22.7% |
| Q3 FY2021 | Sep 30, 2021 | $316.53M | -19.6% |
| Q2 FY2021 | Jun 30, 2021 | $327.51M | +177.9% |
| Q1 FY2021 | Mar 31, 2021 | $351.28M | +152.0% |
| Q4 FY2020 | Dec 31, 2020 | $370.82M | – |
| Q3 FY2020 | Sep 30, 2020 | $393.71M | – |
| Q2 FY2020 | Jun 30, 2020 | $117.85M | – |
| Q4 FY2019 | Dec 31, 2019 | $139.42M | – |
See a number that looks wrong?